thyroxine has been researched along with Hand-Foot Syndrome in 1 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Hand-Foot Syndrome: Chemotherapy-induced dermal side effects that are associated with the use of various CYTOSTATIC AGENTS. Symptoms range from mild ERYTHEMA and/or PARESTHESIA to severe ulcerative dermatitis with debilitating pain involving typically palmoplantar and intertriginous areas. These cutaneous manifestations are sometimes accompanied by nail anomalies.
| Excerpt | Relevance | Reference |
|---|---|---|
| "0%) patients received levothyroxine for hypothyroidism, 24 (8." | 5.30 | Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. ( Chen, W; Cheng, Y; Han, B; Jin, F; Li, K; Luo, Y; Nan, K; Shi, J; Shi, Y; Si, X; Wang, H; Wang, M; Wang, Q; Wang, X; Wang, Z; Zhang, L; Zhang, X, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Si, X | 1 |
| Zhang, L | 1 |
| Wang, H | 1 |
| Zhang, X | 1 |
| Wang, M | 1 |
| Han, B | 1 |
| Li, K | 1 |
| Wang, Q | 1 |
| Shi, J | 1 |
| Wang, Z | 1 |
| Cheng, Y | 1 |
| Shi, Y | 1 |
| Chen, W | 1 |
| Wang, X | 1 |
| Luo, Y | 1 |
| Nan, K | 1 |
| Jin, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Single-arm Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced Non-small Cell Lung Cancer With EGFR 21L858R Mutation[NCT06102928] | 30 participants (Anticipated) | Interventional | 2023-10-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for thyroxine and Hand-Foot Syndrome
| Article | Year |
|---|---|
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects a | 2019 |